Page 110 - 南京医科大学自然版
P. 110

第44卷第7期
               ·994 ·                          南   京 医 科       大 学      学 报                        2024年7月


                                  表1 全球良恶性乳腺病及癌旁、正常乳腺组织的微生物组测序研究情况
              Table 1  Global microbiome sequencing studies of benign and malignant breast disease and paraneoplastic and normal
                      breast tissue

                                                                                                   16S rRNA
               Time    Area          Sample type and sample size         Sequencing method
                                                                                                amplification region
               2023  Morocco [11]  BCT(n=47),NAT( n=47)                 Illumina MiSeq System       V3-V4
                         [12]
               2023   China   BCT(n=18),NAT(n=18),BDT(n=8)         Oxford Nanoporelong⁃read sequencing  -
                         [13]
               2022   USA     NT(n=49),NAT(n=49),BCT(n=61)             Illumina MiSeq sequencing    V3-V4
                         [14]
               2022   USA     Normal adjacent tissues from BDT(n=12),  Illumina MiSeq sequencing      -
                              NAT(n=15)
                              NT(n=6),BCT(n=11),lymphoid metastases
                         [15]
               2022   China                                              Novaseq sequencing           V4
                              tissues(n=4)
                         [16]
               2022   Italy   NAT(n=34),BCT(n=34)                              NGS                  V4-V6
               2022   China [17]  NAT(n=79),normal adjacent tissues from BDT  Illumina Nova Seq 6000 platform  V4
                             (n=15)

               2021  Ireland [18]  BCT(n=23),NAT(n=23),matched skin swab  Illumina MiSeq sequencing  V3-V4
                              samples(n=23)
                         [19]
               2020   USA     BCT(n=10),NT(n=36)                       Illumina MiSeq sequencing    V1-V2
               2020   USA [20]  BCT from black non⁃Hispanic(n=10),matched  Illumina MiSeq sequencing  V3-V4
                              NAT from black non ⁃ Hispanic(n=10), BCT
                              from white non⁃Hispanic(n=23),matched NAT
                              from white non⁃Hispanic(n=23)
               2020   Israel [21]  NT(n=54),BDT(n=29),NAT(n=173),BCT            ⁃                5 short regions
                             (n=355)
                         [22]
               2020   USA     BCT underwent neoadjuvant chemotherapy(n=  Illumina MiSeq sequencing    V4
                              4),BCT with no prior therapy at time of surgery
                             (n=18)
               2019   USA [23]  BCT(n=64),NAT(n=11),NT(n=8)            Illumina MiSeq sequencing      V4
                         [24]
               2018   Italy   BCT(n=19),NAT(n=19)                    Illumina MiSeq Reagent Kit v3  V2、V3、V4、
                                                                                                 V6 、V7、V8、V9
                         [25]
               2018   China   BDT(n=22),BCT(n=72)                      Illumina HiSeq sequencing    V1-V2
               2018   USA [26]  ER positive BCT(n=50),HER2 positive BCT   PathoChip Array             -
                             (n=34),triple positive BCT(n=24),triple
                              negative BCT(n=40),NT(n=20)
                         [27]
               2017   USA     BCT(n=57),NAT(n=57),NT(n=21)             Illumina Miseq sequencing    V3-V4
               2017   USA [28]  BCT(n=668),NAT(n=72)                     Illuminasequencing         V3-V5
               2016  Canada [29]  NAT(n=45),normal adjacent tissues from BDT  Illumina MiSeq sequencing  V6
                             (n=13),NT(n=23)
                         [30]
               2016   USA     NAT(n=15), normal adjacent tissues from  Illumina MiSeq sequencing    V3-V5
                              BDT(n=13)
               2014  Canada [31]  NAT(n=27), normal adjacent tissues from  Ion Torrent platform       V6
                              BDT(n=11),NT(n=5)

                      Ireland  NAT(n=33),NT(n=5)
                         [32]
               2014   USA     BCT(n=20),NAT(n=20)                      Illumina MiSeq sequencing      V4
                 Abbreviation:BCT,breast cancer tissue;BDT,benign disease tissue;NAT,normal adjacent tissue;NT,normal breast tissues.
   105   106   107   108   109   110   111   112   113   114   115